ライフサイエンスコーパス: costimulatory

1 Finally, T-cell costimulatory activity, as measured by mixed lymphocyte

2 rapidly altered their expression of various costimulatory and coinhibitory molecules in a manner tha

3 Costimulatory and coinhibitory receptor-ligand pairs on

4 g CTL dysfunction by altering the balance of costimulatory and coinhibitory signals these cells recei

5 priming with alloantigen, and the net sum of costimulatory and coinhibitory signals transmitted via l

6 activates pathways shared with conventional costimulatory and cytokine receptor signaling.

7 Costimulatory and inhibitory receptors play a key role i

8 cterized by IL-12 production and upregulated costimulatory and lymph node homing molecules on dendrit

9 maturation, as shown by the upregulation of costimulatory and MHC molecules and the production of pr

10 g major histocompatibility complex class-II, costimulatory and proinflammatory mediators, such as int

11 We analyzed the expression of costimulatory and tolerogenic molecules by pulmonary CD1

12 ist (polyinosinic-polycytidylic acid), and a costimulatory anti-CD40 Ab.

13 In contrast, success of agonistic costimulatory antibodies has thus far been limited becau

14 Thus, booster vaccinations with agonistic costimulatory antibodies represent an ideal means to amp

15 that curtailed signaling through the B7-CD28 costimulatory axis during CD8 T cell activation limits t

16 coreceptor engagement, forcing the principal costimulatory axis to signal excessively.

17 iously unrecognized homeostatic role for the costimulatory B7 molecules (CD80 and CD86) in preventing

18 The costimulatory B7-1 (CD80)/B7-2 (CD86) molecules, along w

19 Costimulatory blockade also induced IL-21R expression in

20 Finally, successful use of costimulatory blockade and B-cell depletion in the clini

21 new insights into the tolerogenic effects of costimulatory blockade and identify DC-SIGN(+) suppressi

22 emory T cells, which are less susceptible to costimulatory blockade by belatacept, or resulted from i

23 ow NK cells promote allograft survival under costimulatory blockade conditions by regulating alloreac

24 ell-mediated skin transplant rejection under costimulatory blockade conditions.

25 late alloreactive CD8+ Tcell responses under costimulatory blockade conditions.

26 In particular, costimulatory blockade did not change other previously d

27 Here, we demonstrate that costimulatory blockade favored accumulation of DC-SIGN-e

28 s not impact the graft-prolonging effects of costimulatory blockade including that induced by clinica

29 Costimulatory blockade increased IL-10 in marginal zone

30 expression of the VD receptor (VDR) impacts costimulatory blockade induced cardiac allograft surviva

31 CD40 costimulatory blockade induces MZP B cell IL-10 which is

32 The BALB/c-mice also received costimulatory blockade through multiple-doses of anti-CD

33 terotopic cardiac allografts with or without costimulatory blockade using anti-CD154 (MR1) or CTLA4Ig

34 ignificantly prolonged allograft survival on costimulatory blockade when compared to Rag1-/-T-bet-/-

35 Costimulatory blockade with anti-CD40L monoclonal antibo

36 B-cell depletion prevented costimulatory blockade-induced allogeneic tolerance.

37 Alloreactive memory T cells prevent costimulatory blockade-induced heart graft survival in m

38 Here, using a murine model, we found that costimulatory blockade-mediated lung allograft acceptanc

39 tivation of alloreactive T cells despite the costimulatory blockade.

40 ficient to cause rejection in the context of costimulatory blockade.

41 chanistic target of rapamycin inhibition and costimulatory blockade.

42 ted with perioperative administration of the costimulatory blocking agent CTLA4 immunoglobulin exhibi

43 eover, despite unaltered Ag presentation and costimulatory capabilities, Myo9b(-/-) DCs were poor T c

44 cultured with T cells in vitro, have a lower costimulatory capacity.

45 Costimulatory cascades such as the CD40L-CD40 dyad enhan

46 f atypical, cytotoxic CD4(+) T cells lacking costimulatory CD28 (CD4(+) CD28(null) cells) is associat

47 time, has been shown to trigger the loss of costimulatory CD28 molecules with recently reported inte

48 ress immune reactions by blocking the T-cell costimulatory CD28-CD80-86 pathway and are used in clini

49 Blocking of costimulatory CD28/B7 and CD40/CD40L interactions is an

50 pic challenge, indicating a novel role for a costimulatory cytokine in recall responses.

51 hat CD19 CAR T cells incorporating the 4-1BB costimulatory domain are more persistent than those inco

52 Ts was not mitigated by the incorporation of costimulatory domains, such as 4-1BB, into the CD19-CAR.

53 eractions in obesity and discuss the role of costimulatory dyads in its pathogenesis.

54 ion of T-cell coinhibitory (e.g., CTLA-4) or costimulatory (e.g., 4-1BB) receptors promotes clinical

55 that the CD2-CD58 interaction has a genuine costimulatory effect on this T cell subset.

56 CD80 elongation reduced its costimulatory effect without abrogating CD28 binding.

57 We used REAP-seq to assess the costimulatory effects of a CD27 agonist on human CD8(+)

58 n to influence immune responses through both costimulatory effects on effector T cells and opposing i

59 how that, in contrast to its well-documented costimulatory effects, CD40 regulates development of ins

60 specific CAR (CD30.CAR-Ts) encoding the CD28 costimulatory endodomain.

61 n alone, with CD28, 4-1BB, or CD28 and 4-1BB costimulatory endodomains.

62 hat merely trigger immune responses, whereas costimulatory events specify the type of reaction.

63 TIGIT and the costimulatory factor CD226 bind the common ligand CD155.

64 igh expression of inflammatory mediators and costimulatory factors.

65 Costimulatory function and cytokine modulation by CD55 w

66 ient for isoforms of ICAM-1, which comediate costimulatory functions, spontaneously develop a chronic

67 renal community, implying that abatacept, a costimulatory inhibitor that targets B7-1, could be a no

68 Costimulatory interactions are required for T cell activ

69 We show that CD28-CD80/86 and CD40-CD40L costimulatory interactions, which mediate negative selec

70 d whether selective blockade of CD28-CD80/86 costimulatory interactions, which preserves the coinhibi

71 ta, we propose that Tregs locally change the costimulatory landscape in tumor tissue through transien

72 a novel role for IL-21 as an inducer of the costimulatory ligand CD86 on B lymphocytes.

73 Costimulatory ligand expression by DCs and T cell prolif

74 Moreover, we demonstrate that the costimulatory ligand ICOS ligand (ICOSL) is selectively

75 here was no evidence for the upregulation of costimulatory ligands or cytokine secretion.

76 nes that were engineered to express CD1d and costimulatory ligands.

77 in upregulation of antigen presentation and costimulatory machinery in adult, but not fetal, monocyt

78 B cells lacked the ability to upregulate the costimulatory marker CD40, suggesting IDO2 acts at the T

79 DC expression of the costimulatory marker CD86 was significantly reduced in a

80 of airway DC with reduced expression of the costimulatory marker CD86, suggesting altered traffickin

81 mmatory cytokine production, upregulation of costimulatory markers, and activation of T cells.

82 erived dendritic cells (moDC) and lower moDC costimulatory maturation.

83 Here, we have shown that expression of the costimulatory molecule and microbial sensor SLAMF1 (also

84 uence TCR repertoire diversity by modulating costimulatory molecule availability.

85 The costimulatory molecule CD137 (4-1BB) is expressed follow

86 The costimulatory molecule CD161 is expressed on lymphocyte

87 rom patients exhibited downregulation of the costimulatory molecule CD226, which competes with TIGIT

88 Here, we unravel the role of the costimulatory molecule CD40 and its signaling intermedia

89 The costimulatory molecule CD40 enhances immunity through se

90 The costimulatory molecule CD40 is a major driver of atheros

91 duced the expression of MHC class II and the costimulatory molecule CD40 on the surface of the cells.

92 mation of memory T cells, which requires the costimulatory molecule CD70 on antigen-presenting cells,

93 ter, they decrease surface expression of the costimulatory molecule CD80 on the DCs.

94 , we provide evidence that hBD-3 induces the costimulatory molecule CD86 on primary human monocytes b

95 r histocompatibility complex II (MHC II) and costimulatory molecule CD86, decreasing production of Th

96 node, as well as increased expression of the costimulatory molecule CD86.

97 CD48 (SLAMF2) is an adhesion and costimulatory molecule constitutively expressed on hemat

98 Here, we investigated the role of the costimulatory molecule DNAM-1 in the differentiation of

99 djuvant induces MHC class II, CD80, and CD86 costimulatory molecule expression and dendritic cell mat

100 LR9 agonists, as well as TLR agonist-induced costimulatory molecule expression and TNF-a (but not IL-

101 ass-switched memory B cells and intermediate costimulatory molecule expression between naive and clas

102 Notably, related to the high-level costimulatory molecule expression induced by lymphocytic

103 ng technology, and measurement of MHC II and costimulatory molecule expression on DCs by using flow c

104 he presence of cis-UCA significantly reduced costimulatory molecule expression on monocyte-derived de

105 nsion with diminished cytokine but increased costimulatory molecule expression, and capacity for prof

106 red the release of TH1-polarizing cytokines, costimulatory molecule expression, and T-cell activation

107 ough alum-adjuvanted vaccines induced modest costimulatory molecule expression, limited TH-polarizing

108 to increased dendritic cell (DC) numbers and costimulatory molecule expression.

109 , whereas cDCs are most efficient in MHC and costimulatory molecule expression.

110 ell-specific molecule that serves as a major costimulatory molecule for amplifying B-cell receptor (B

111 of apoptotic cells, and it may also act as a costimulatory molecule for immune cells.

112 Mechanistically, the costimulatory molecule ICOS activated mTORC1 and mTORC2

113 L-21); Foxp1 also dampened expression of the costimulatory molecule ICOS and its downstream signaling

114 Homotypic interactions between the costimulatory molecule ICOS and the ICOS ligand on MDDCs

115 Purpose CD27, a costimulatory molecule on T cells, induces intracellular

116 on between ILC2s and CD4(+) T cells involved costimulatory molecule OX40L and cytokine IL-4, which wa

117 ns, we evaluated a combination of the T-cell costimulatory molecule SA-4-1BBL with the TLR4 agonist m

118 Here, we utilized the benefits of CD40L, a costimulatory molecule that can stimulate both dendritic

119 ent raptor to an aptamer that binds 4-1BB, a costimulatory molecule that is expressed on CD8(+) T cel

120 esponses, or myeloid antigen-presenting cell costimulatory molecule upregulation.

121 ILC2s express ICOS, a T cell costimulatory molecule with a currently unknown function

122 oid-induced TNFR-related protein (GITR) is a costimulatory molecule with diverse effects on effector

123 B7h, which is the ligand of the ICOS T cell costimulatory molecule.

124 , the authors used a second generation 4-1BB costimulatory-molecule-based chimeric antigen receptor (

125 e (HLA-DR(+), CD38(+), Bcl-2(lo)), expressed costimulatory molecules (CD28, CD27, ICOS), and had high

126 ng in a sharp inhibition of MHC class II and costimulatory molecules (CD40, CD86) expression as well

127 its) and enhanced expression of MHC-E and of costimulatory molecules (CD70 and CD80, but not CD86).

128 se to stimulation, fibroblasts expressed the costimulatory molecules 4-1BBL, OX-40L, and CD70, all of

129 s, as indicated by defective upregulation of costimulatory molecules and CD83, as well as reduced sec

130 ed with polyU, as well as by upregulation of costimulatory molecules and increased secretion of proin

131 These DCs did not upregulate costimulatory molecules and induced regulatory T cells r

132 r)NOD mice features an altered expression of costimulatory molecules and induces neuritis and myelin

133 s and strongly upregulated the expression of costimulatory molecules and production of proinflammator

134 to a reduced activation profile with reduced costimulatory molecules and proinflammatory cytokine pro

135 y unusual phenotype by which DCs up-regulate costimulatory molecules and secretion of chemokines, but

136 a process involving up-regulation of MHC and costimulatory molecules and secretion of proinflammatory

137 Nano-11 induced increased expression of costimulatory molecules and the secretion of IL-1beta an

138 t2(-/-) cDCs displayed reduced expression of costimulatory molecules and type I IFN-stimulated genes.

139 Signals delivered by costimulatory molecules are implicated in driving T cell

140 broad spectrum of cytokines and cell-surface costimulatory molecules are known to shape the programmi

141 eightened cell surface expression of MHC and costimulatory molecules as well as cytokine production.

142 d cytokine release and surface expression of costimulatory molecules by untreated or inhibitor-treate

143 tivation and increased the expression of the costimulatory molecules CD27 and CD40L.

144 F2 deficiency enhanced surface expression of costimulatory molecules CD40 and CD86 in DCs and promote

145 so induced higher levels of MHC class II and costimulatory molecules CD40 and CD86, indicating that M

146 ession of the maturation marker CD83 and the costimulatory molecules CD40, CD80, and CD86, decreased

147 leukocyte antigen antigen D related and the costimulatory molecules CD40, CD80, and CD86.

148 ass I and the PD-1 ligand PD-L1, but not the costimulatory molecules CD40, CD80, or CD86, upon Ag-spe

149 patibility complex class II (MHC-II) and the costimulatory molecules CD80 and CD86 on CD11c+ CD11b+ m

150 professional APCs and the expression of the costimulatory molecules CD80/86 for efficient CD8 T cell

151 h was explained by increased upregulation of costimulatory molecules CD86 and MHC class II on moDCs i

152 efects in the expression of MHC class II and costimulatory molecules corresponded with a reduced capa

153 ng between numerous adhesion, signaling, and costimulatory molecules defines both the topographical a

154 Changes in expression of costimulatory molecules did not explain loss of function

155 aling, and a diverse set of coinhibitory and costimulatory molecules during CD4(+) T cell exhaustion.

156 C maturation markers such as MHC class I and costimulatory molecules following infection with the clo

157 Our study showed that most costimulatory molecules have a low capacity to activate

158 proliferation and expression of effector and costimulatory molecules in a tumor antigen-dependent man

159 should be considered when using cytokines as costimulatory molecules in fusion proteins.

160 proinflammatory cytokines and expression of costimulatory molecules in mouse macrophages.

161 RIP-B7.1 transgenic mice express B7.1 costimulatory molecules in pancreatic islets and develop

162 While adhesion and costimulatory molecules in the immunological synapse imp

163 ential of therapeutic strategies that target costimulatory molecules in the metabolic syndrome is exp

164 fficacy in multiple cancers, but the role of costimulatory molecules in this T cell rescue remains el

165 in activates DCs to induce the expression of costimulatory molecules in vitro.

166 pecific expression of several chemokines and costimulatory molecules indicated in thymocyte developme

167 Analysis of costimulatory molecules indicated that, relative to resi

168 mphoma cell line and prevent upregulation of costimulatory molecules of LPS-stimulated human dendriti

169 Costimulatory molecules of the CD28 family on T lymphocy

170 Costimulatory molecules of the tumor necrosis factor/tum

171 g with the TCR; signal 2, the interaction of costimulatory molecules on T cells and APCs; and signal

172 pregulation of CD54, CD86, OX40L, and 4-1BBL costimulatory molecules on the neutrophil surface, which

173 mental Ags, acting in part by downmodulating costimulatory molecules on the surface of dendritic cell

174 using agonostic/antagonistic Abs to various costimulatory molecules or their receptors, that the gre

175 PSA is better at enhancing PDC expression of costimulatory molecules required for protection against

176 viral genomes or to differences in levels of costimulatory molecules required for this interaction.

177 can be improved by coupling Env proteins to costimulatory molecules such as a proliferation inducing

178 ibitory receptor, but also expressed several costimulatory molecules such as ICOS and CD28.

179 y cytokine secretion and the upregulation of costimulatory molecules upon TLR stimulation.

180 major histocompatibility complex class I and costimulatory molecules were significantly higher in MER

181 cells (BMDCs) compared to WT BMDCs, although costimulatory molecules were upregulated in both types o

182 hibit modestly reduced surface expression of costimulatory molecules whose expression is similarly de

183 Secretion of cytokines, upregulation of costimulatory molecules, and Ag degradation were abrogat

184 e, they have low expression of MHC class II, costimulatory molecules, and low arginase1 expression.

185 ression of functional MHC-peptide complexes, costimulatory molecules, and other components that inter

186 -kappaB nuclear translocation, expression of costimulatory molecules, and production of immunogenic c

187 lation of dendritic cell maturation markers, costimulatory molecules, and secretion of proinflammator

188 the expression of dendritic cells (DCs) and costimulatory molecules, B cells, T cells, TH2-related c

189 The costimulatory molecules, B7.1 and B7.2, are important re

190 profiles by downmodulating MHC class II and costimulatory molecules, but strengthens innate signatur

191 sphingosine kinase 1, CCL1, arginase-1, and costimulatory molecules, CD16/32, ICAM-1, as well as PD-

192 o TLR agonists, as they failed to upregulate costimulatory molecules, secrete significant amounts of

193 A deficiency in costimulatory molecules, such as B7-2, on the NOD geneti

194 Costimulatory molecules, such as the programmed death li

195 ure phenotype characterized by downregulated costimulatory molecules, the release of low amounts of p

196 Costimulatory molecules, which are present on antigen-pr

197 s by increasing the expression of HLA-DR and costimulatory molecules, which resulted in improved indu

198 and large airways, which express HLA-DR and costimulatory molecules.

199 not due to diminished upregulation of MHC or costimulatory molecules.

200 creased expression of both the CD80 and CD86 costimulatory molecules.

201 surface MHC class II molecules, and express costimulatory molecules.

202 6 and increased surface expression of T cell costimulatory molecules.

203 s and events occurring downstream of TCR and costimulatory or coinhibitory receptor engagement.

204 ation rather than differential expression of costimulatory or inhibitory molecules.

205 In addition, the CD28-CD80/86 costimulatory pathway appeared to be sufficiently blocke

206 ly identify the CD58/CD2 axis as the primary costimulatory pathway for CD8 T cells that lack CD28.

207 to self-peptide ligand may represent a novel costimulatory pathway for LIP.

208 Inhibition of the CD28:CD80/CD86 T cell costimulatory pathway has emerged as an effective strate

209 nti-CD40 antibodies targeting the CD40/CD154 costimulatory pathway has just completed a phase II tria

210 ction and now question the role of the 4-1BB costimulatory pathway in the cross-talk between these ce

211 Here, we demonstrate that the CD28/B7 costimulatory pathway is essential for effective PD-1 th

212 Triggering the 41BB costimulatory pathway may be a strategy for enhancing T

213 The CD27/CD70 costimulatory pathway was shown to be critical for T cel

214 Belatacept, an inhibitor of the CD28-CD80/86 costimulatory pathway, allows for calcineurin-inhibitor

215 ally and uniquely dictate the utilization of costimulatory pathways allowing shaping of effector and

216 In addition to TCR signaling, costimulatory pathways are involved in T cell activation

217 rate that immunotherapies that target T cell costimulatory pathways block the rejection of xenogeneic

218 ivo, demonstrating a critical role for these costimulatory pathways in self-tolerance as well as thym

219 One of the best-characterized costimulatory pathways includes the Ig superfamily membe

220 D8(+) T cells because of redundancy with the costimulatory pathways induced by TNF receptor family me

221 that have addressed how major inhibitory and costimulatory pathways play a role in regulating immune

222 inactivating CD28 signaling, suggesting that costimulatory pathways play key roles in regulating effe

223 his study, we have examined such alternative costimulatory pathways regarding their functional role i

224 innate-like T cells by providing alternative costimulatory pathways that gain relevance in chronic in

225 sion of both CTLA4-Ig, which disrupts T cell costimulatory pathways, and PD-L1, which activates T cel

226 Downstream of costimulatory pathways, complexes of transcription facto

227 include selective CD28 blockade to block the costimulatory potential of CD28 while exploiting the coi

228 expression was associated with a decrease in costimulatory potential.

229 mental to T-cell memory, we incorporated its costimulatory properties by coexpressing CAR with a memb

230 The costimulatory properties of second-generation chimeric a

231 rface molecule CD83, which was shown to have costimulatory properties, is targeted by herpes simplex

232 Recent studies implicated a B7-like negative costimulatory protein, V-set domain-containing T-cell ac

233 possibility of small-molecule inhibition of costimulatory protein-protein interactions, establish th

234 IL-6, IL-1beta, and IL-23 and an increase in costimulatory proteins CD80 and CD86.

235 Of relevance the costimulatory proteins CD80/CD86, signals needed for reg

236 the tumor-reactive population expressed the costimulatory receptor 4-1BB (also known as CD137).

237 Expression of the costimulatory receptor 4-1BB is induced by TCR recogniti

238 Activation of costimulatory receptor CD137 with mAb (4-1BB) exerted st

239 nd nonoverlapping roles for the noninducible costimulatory receptor CD28 and the inflammatory cytokin

240 ells via engagement of the prototypic T cell costimulatory receptor CD28 by the cognate ligands CD80/

241 previously shown that the prototypic T-cell costimulatory receptor CD28, which is also expressed on

242 he T cell antigen receptor and the principal costimulatory receptor CD28.

243 -activation factor (BAFF), the ligand of the costimulatory receptor CD40 (CD40L) and the Notch ligand

244 ctor receptor superfamily 9) is an inducible costimulatory receptor expressed on activated T and natu

245 alpha and gp130, enhancing expression of the costimulatory receptor ICOS and promoting expression of

246 Although both cell types express the costimulatory receptor ICOS and require the transcriptio

247 lethality by blocking the superantigen-host costimulatory receptor interaction.

248 tes, we have recently demonstrated that CD28 costimulatory receptor is crucial for regulating PIP2 tu

249 cyte activation molecule 6 expression, a TCR costimulatory receptor required for NKT cell development

250 GITR is a T-cell costimulatory receptor that enhances cellular and humora

251 diminished innate (dendritic cell cytokines, costimulatory receptor, and apoptotic) and adaptive (CD4

252 t has been identified as an important T cell costimulatory receptor, and patients deficient in CD46 o

253 CD28 acts as the primary T cell costimulatory receptor, but there are numerous additiona

254 rogated by blockade of TIGIT's complementary costimulatory receptor, CD226, whose dimerization is dis

255 tail replaced by the signaling domain of the costimulatory receptor, CD28.

256 II molecules ("signal 1"), upregulate T cell costimulatory receptors ("signal 2"), and secrete "signa

257 activation requires interaction between the costimulatory receptors B7-2 and CD28.

258 Whereas costimulatory receptors such as ICOS are accepted as bei

259 ich require signals generated by the TCR and costimulatory receptors to become fully activated, naive

260 for the clustering of lipid rafts, TCR, and costimulatory receptors toward the T:APC interface.

261 transmitting intracellular signals from Ag, costimulatory receptors, and cytokine receptors to contr

262 ally requires engagement of both the TCR and costimulatory receptors, such as CD28.

263 considered to be members of the B7 family of costimulatory receptors, which includes B7.1 (CD80), B7.

264 T cell receptor alone or in combination with costimulatory receptors.

265 lexes are internalized by T cells and induce costimulatory responses independently of known NA sensor

266 We hypothesized that blockade of the T cell costimulatory signal by the CTLA4-Ig synthetic protein (

267 The precise costimulatory signal requirements for proper TFR cell di

268 ellin, a TLR5 ligand (TLR5L), can engender a costimulatory signal that augments antitumor activity.

269 T-cell coregulatory receptor that provides a costimulatory signal to T cells during antigen-mediated

270 de/protein Ag and an agonist that delivers a costimulatory signal via CD27 or 4-1BB.

271 The CD27-CD70 pathway is known to provide a costimulatory signal, with CD70 expressed on APCs and CD

272 7-H3 is responsible for providing a negative costimulatory signal.

273 hed tumors with provision of a suitable CD28 costimulatory signal.

274 to cytotoxic effector cells upon therapeutic costimulatory signaling and restore antitumor immunity.

275 hage migration inhibitory factor and provide costimulatory signaling during naive CD4(+) T cell primi

276 ion potentially modulate the requirement for costimulatory signaling for osteoclast differentiation a

277 This requirement for costimulatory signaling is maintained even in a TCR tran

278 y targeted activation of multiple innate and costimulatory signaling pathways, such as CD40 or TLRs.

279 nate immune cells that are a major source of costimulatory signals and inflammatory mediators in the

280 It is not well understood how costimulatory signals are regulated and integrated with

281 TCR signaling in the absence of costimulatory signals can lead to an abortive attempt at

282 ha-4-1BB antibody is known to provide strong costimulatory signals for augmenting and diversifying T-

283 ires activation of RANK signaling as well as costimulatory signals from immunoreceptor tyrosine-based

284 Blocking CD40-CD40L costimulatory signals induces transplantation tolerance.

285 T cells, indicating that the requirement for costimulatory signals is not imprinted.

286 tified PIP5Kalpha as a key modulator of CD28 costimulatory signals leading to the efficient T cell ac

287 Survival or costimulatory signals rescue B cells from this fate, but

288 1A (TL1A) is expressed on APCs and provides costimulatory signals to activated lymphocytes that bear

289 CD27 signaling provides costimulatory signals to cytotoxic T cells but also incr

290 DC maturation is necessary to provide costimulatory signals to T cells, but while DC maturatio

291 y presenting microbial antigen and providing costimulatory signals to T cells.

292 a primary recognition signal and additional costimulatory signals.

293 ation through a combination of integrins and costimulatory signals.

294 ic CD8(+) T cells is slightly redundant with costimulatory signals.

295 tor function following initial activation by costimulatory signals.

296 ses by providing either positive or negative costimulatory signals.

297 e tuned to alter their motility depending on costimulatory signals.

298 expansion and effector function by providing costimulatory signals.

299 Tregs express several costimulatory TNF receptor family members that activate

300 The costimulatory TNFR family member GITR can provide import